Pharming Group N.V.
PHGUF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $97,287 | $93,221 | $79,094 | $92,672 |
| % Growth | 4.4% | 17.9% | -14.7% | – |
| Cost of Goods Sold | $7,071 | $8,972 | $8,323 | $12,213 |
| Gross Profit | $90,216 | $84,249 | $70,771 | $80,459 |
| % Margin | 92.7% | 90.4% | 89.5% | 86.8% |
| R&D Expenses | $23,384 | $23,695 | $21,142 | $21,642 |
| G&A Expenses | $16,954 | $20,505 | $22,486 | $46,082 |
| SG&A Expenses | $51,081 | $51,554 | $57,056 | -$38,646 |
| Sales & Mktg Exp. | $34,127 | $31,049 | $34,570 | -$84,728 |
| Other Operating Expenses | -$72 | -$1,849 | -$383 | $90,759 |
| Operating Expenses | $74,393 | $73,400 | $77,815 | $73,755 |
| Operating Income | $15,823 | $10,849 | -$7,044 | $6,704 |
| % Margin | 16.3% | 11.6% | -8.9% | 7.2% |
| Other Income/Exp. Net | -$3,065 | -$3,770 | -$4,744 | -$26 |
| Pre-Tax Income | $12,758 | $7,079 | -$11,788 | $6,678 |
| Tax Expense | $5,209 | $2,529 | $3,100 | $3,819 |
| Net Income | $7,548 | $4,694 | -$14,719 | $3,591 |
| % Margin | 7.8% | 5% | -18.6% | 3.9% |
| EPS | 0.011 | 0.007 | -0.022 | 0.005 |
| % Growth | 61.4% | 131.8% | -540% | – |
| EPS Diluted | 0.011 | 0.007 | -0.022 | 0.005 |
| Weighted Avg Shares Out | 669,045 | 685,148 | 669,045 | 680,309 |
| Weighted Avg Shares Out Dil | 669,045 | 685,148 | 669,045 | 680,309 |
| Supplemental Information | – | – | – | – |
| Interest Income | $485 | $659 | $604 | $1,098 |
| Interest Expense | $7,946 | $4 | $5,098 | $2,426 |
| Depreciation & Amortization | $2,726 | $2,702 | $2,582 | $7,699 |
| EBITDA | $23,430 | $9,785 | -$4,108 | $15,626 |
| % Margin | 24.1% | 10.5% | -5.2% | 16.9% |